Our result complemented those of a previous study implying that RGC death was prevented in the absence of TXNIP under retinal neurodegeneration, indicating the possible prospects of TXNIP as a new endogenous therapeutic target for neuroprotection in glaucoma (Ao et al. 2021). Here, TXNIP is linked to glaucoma.